5 active not recruiting, 4 recruiting, 1 completed, 1 terminated. 5 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Recruiting 2, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 2, Withdrawn 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Unresectable Pancreatic Adenocarcinoma: new trials by email Literature Review of Unresectable Pancreatic Adenocarcinoma trials Research Report on Unresectable Pancreatic Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma TR-002 - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | University of California, Davis | 52 | 2025-11-07 | 2026-07-16 |
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 24 | 2024-12-06 | 2026-06-18 |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Onvansertib, Gemcitabine, Nab-paclitaxel - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2024-08-01 | 2024-07-19 | |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Recruiting | University of Rochester | 800 | 2023-12-04 | 2026-01-09 | |
| PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Biospecimen Collection, Computed Tomography, Distal Pancreatectomy - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8 | Not applicable | Active not recruiting | University of Southern California | 2 | 2023-12-01 | 2025-11-25 |
| Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 58 | 2022-10-05 | 2026-10-02 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-10-20 | 2026-09-10 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients wrist-worn accelerometer, Auto-questionnaires - Unresectable Pancreatic Adenocarcinoma | Completed | Centre Hospitalier Universitaire Dijon | 30 | 2018-07-02 | 2022-01-26 | |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 122 | 2016-08-31 | 2026-09-25 |
Pancreatic Neoplasms (9) · Neoplasm Metastasis (4) · Breast Neoplasms (2) · Lung Neoplasms (2) · Small Cell Lung Carcinoma (2) · Anemia (1) · Blast Crisis (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Neoplasms (10) · Neoplasms by Site (10) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Pancreatic Diseases (9) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Breast Diseases (2)
Specimen Handling (9) · Magnetic Resonance Spectroscopy (6) · Biopsy (4) · 130-nm albumin-bound paclitaxel (3) · Albumin-Bound Paclitaxel (3) · Fluorouracil (3) · Gemcitabine (3) · Irinotecan (3) · Leucovorin (3) · Taxes (3) · dehydroftorafur (3) · BAY 1895344 (2) · Oxaliplatin (2) · neratinib (2) · olaparib (2)
National Cancer Institute (NCI) (4) · OHSU Knight Cancer Institute (2) · Centre Hospitalier Universitaire Dijon (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1) · University of California, Davis (1) · University of Rochester (1) · University of Southern California (1)
United States (11) · Canada (1) · France (1)
Andrew Davis (1) · Charles D Lopez (1) · Edward J Kim, MD, PhD (1) · James M Cleary (1) · Joseph W Kim (1) · Lara Davis, MD (1) · Rachael A Safyan (1) · Richard F Dunne (1) · Steven R Grossman, MD (1) · Thatcher Heumann (1) · Vinay Chandrasekhara, MD (1)
PMID 37597578, PMID 39863139, PMID 42247927
UM1CA186689 (3), P01CA084203 (1), P30CA014089 (1), P30CA093373 (1), U10CA180888 (1), UG1CA189961 (1), UM1CA186644 (1), UM1CA186709 (1)